• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Fluorine‐18‐fluorodeoxyglucose‐positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal‐related events
【24h】

Fluorine‐18‐fluorodeoxyglucose‐positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal‐related events

机译：肺癌转移性骨病变中的氟-18-氟脱氧葡萄糖 - 正电子发射断层扫描评价：可能预测疼痛和骨骼相关事件

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) uptake in primary lesions has been well studied, but little information is available about metastatic bone lesions in patients with lung cancer. The present study was performed to evaluate the relationships between metastatic bone FDG uptake and clinical parameters in patients with lung cancer. FDG uptake was evaluated as the maximum standardized uptake (SUVmax) value of each targeted bone lesion, and the bone to primary lesion ratio of SUVmax (B/P ratio) was calculated. Forty-nine patients (27 men and 22 women) with a diagnosis of lung cancer (small cell lung cancer [SCLC], n?=?7; non-small cell lung cancer [NSCLC], n?=?42) with bone metastasis, and a total of 185 bone metastatic lesions were evaluated. The SUVmax in bone and the B/P ratio were significantly higher in patients with pain and subsequent development of skeletal-related events than in those without pain or skeletal-related events, respectively. In addition, the SUVmax in metastatic bone lesions and the B/P ratio in SCLC were significantly lower than those in NSCLC, despite similar FDG uptake in the primary tumor. Our findings suggest that FDG-PET evaluation in metastatic bone lesions could be useful to predict initial pain and subsequent clinical outcomes of local bone status in initially diagnosed lung cancer patients with bone metastasis. In addition, our results suggest that there could be histological differences in the biological activity of bone metastatic lesions in lung cancer, especially between SCLC and NSCLC. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：研究了氟-18-氟脱氧血糖-Corlron排放断层扫描（FDG-PET）的主要病变吸收，但肺癌患者的转移性骨病变很少有信息。进行本研究以评价肺癌患者转移性骨FDG摄取和临床参数之间的关系。评估FDG摄取为每个靶向骨病变的最大标准化摄取（SUVMAX）值，并计算骨骼与SUVMAX（B / P比）的初级病变比。四十九名患者（27名男性和22名女性）诊断肺癌（小细胞肺癌[SCLC]，N？7;非小细胞肺癌[NSCLC]，N？= 42）与骨骼转移，并评估总共185个骨转移性病变。骨骼中的骨骼和B / P比的Suvmax分别在骨骼相关事件的疼痛和随后的发展中显着高于骨骼相关事件，而不是在没有疼痛或骨骼相关事件的情况下。此外，尽管原发性肿瘤中有类似的FDG吸收，但SCLC中的SUVMAX和SCLC中的B / P比率显着低于NSCLC中的骨质骨质病变显着低。我们的研究结果表明，转移性骨病变中的FDG-PET评估可用于预测最初诊断肺癌患者骨转移的局部骨状况的初始疼痛和随后的临床结果。此外，我们的结果表明，肺癌中骨转移性病变的生物活性可能存在组织学差异，尤其是SCLC和NSCLC之间的骨转移性病变。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号